NICE recommends reviewing GLP-1 treatment at six months and continuing only with meaningful HbA1c reduction (11 mmol/mol) and 3% weight loss
This is a predictable pattern that catches many users off guard
Researchers analysed data from a cohort of 46,334 patients with diabetes who had been exposed to GLP-1 RAs for six months or more, and 92,668 unexposed matched patients with diabetes
Side Effects, Safety Monitoring, and Clinical Support GLP-1 medications cause nausea, vomiting, and constipation in a significant proportion of userstypically mild and transient with slow dose escalation, but worth monitoring
Conclusion: A Call to Action As pharmacovigilance professionals, our mission is to protect patients from adverse drug reactions, including the frequently overlooked problem of drug-induced nightmares